Previous 10 | Next 10 |
2024-02-15 10:18:57 ET Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and r...
2024-02-14 15:20:31 ET More on Incyte Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript Incyte Corporation 2023 Q4 - Results - Earnings Call Presentation Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Incyte Q4 2023 ...
2024-02-14 09:15:02 ET Truist Financial analyst issues MARKET OUTPERFORM recommendation for INCY on February 14, 2024 09:00AM ET. The previous analyst recommendation was Market Outperform. INCY was trading at $59.34 at issue of the analyst recommendation. The overall ana...
2024-02-14 09:15:02 ET Mizuho Securities analyst issues UNDERPERFORM recommendation for INCY on February 14, 2024 09:00AM ET. The previous analyst recommendation was Underperform. INCY was trading at $59.34 at issue of the analyst recommendation. The overall analyst cons...
2024-02-13 15:50:11 ET Summary AbCellera Biologics Inc. saw a significant decline in revenue due to the end of the COVID-19 pandemic, but has a large cash hoard and continues to expand partnerships. Analyst firms continue to Buy/Outperform ratings on the stock, but the company's p...
2024-02-13 12:37:03 ET Incyte Corporation (INCY) Q4 2023 Earnings Conference Call February 13, 2024, 08:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Hervé Hoppenot - Chief Executive Officer Barry Flannelly - General...
2024-02-13 07:10:06 ET Incyte press release ( NASDAQ: INCY ): Q4 Non-GAAP EPS of $1.06 misses by $0.09 . Revenue of $1.01B (+9.0% Y/Y) beats by $10M . 2024 Financial Guidance ... Read the full article on Seeking Alpha For further details s...
Total FY'23 net product and royalty revenues of $3.7 billion (+14% Y/Y); total FY'23 net product revenues of $3.2 billion (+15% Y/Y) Jakafi ® (ruxolitinib) net revenues of $2.6 billion (+8%) for FY'23; Jakafi net revenues guidance range of $2,690 - $2,750 million for FY 2024 ...
ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...
2024-02-12 11:41:12 ET More on Incyte Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Incyte buys global rights for tafasitamab from MorphoSys Agilent, Incyte to collaborate on companion diagnostics development Seeking Alpha...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...